AN INNOVATIVE PREP RESEARCH STUDY FOR WOMEN
HPTN 084 (LIFE) is a research study that compares the effectiveness of injections and oral tablets as pre-exposure prophylaxis (PrEP) to prevent HIV in women.
CABOTEGRAVIR FOR PREP
HPTN 084 (LIFE) is the first study to test if an injection of cabotegravir (CAB) given once every two months works better than a Truvada pill taken every day for HIV prevention in women. Truvada consists of the two anti-HIV drugs – emtricitabine and tenofovir disoproxil fumarate (TDF/FTC).
HPTN 084 is a study that is part of the NIH-DAIDS-funded HIV Prevention Trials Network (HPTN). Learn more under Additional Information.